The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer

Breast Cancer Research and Treatment

Volumn 49, Issue 2, 1998, Pages 155-164

  Goodson III, William H ^a,b,c   Moore II, Dan H ^a,b   Ljung, Britt Marie ^a   Chew, Karen ^a   Florendo, Carmina ^a   Mayall, Brian ^a   Smith, Helene S ^b   Waldman, Frederic M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Breast cancer; Bromodeoxyuridine; Functional relationship; Human study; In vivo; Ki 67; Prognosis; Proliferation markers

Indexed keywords

BROXURIDINE; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CELL COUNT; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA SYNTHESIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STATISTICS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BROMODEOXYURIDINE; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; RISK FACTORS;

EID: 0031813372     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005926228093     Document Type: Article

References (23)

1. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
2. Meyer JS, Province M: Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12: 191-204, 1988
3. Hoshino T, Wilson CB: Cell kinetics of human brain tumors (gliomas). Cancer 44: 956-962, 1979
4. 3H thymidine labeling in human breast cancers. Modern Pathol 4: 718-722, 1991
5. Goodson WH 3d, Ljung BM, Waldman F, Mayall B, Chew K, Moore DH 2d, Smith HS, Goldman ES, Benz C: In vivo measurement of breast cancer growth rate. Arch Surg 126: 1220-1223, 1991
6. Goodson WH 3d, Ljung BM, Moore DH 2d, Mayall B, Waldman FM, Chew K, Benz C, Smith HS: Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 71: 3914-3919, 1993
7. Stanton PD, Cooke TG, Forster G, Smith D, Going JJ: Cell kinetics in vivo of human breast cancer. Br J Cancer 83: 98-102, 1996
8. Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL: Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335-341, 1989
9. Potten CS, Kellett M, Roberts SA, Rew DA, Wilson GD: Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. Gut 33: 71-78, 1992
10. Erba E, Giordano M, Danova M, Mazzini G, Ubezio P, Torri V, Mangioni C, Landoni F, Bolis P, Tenti P: Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Ann Oncol 5: 627-634, 1994
11. Wilson GD, Dische S, Saunders MI: Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Radiotherapy Oncol 36: 189-197, 1995
12. Tinnemans MMFJ, Lenders MHJH, ten Velde GPM, Wagenaar SS, Blijham GH, Ramaekers FC, Schutte B: Evaluation of proliferation parameters in in vivo bromodeoxyuridine labeled lung cancers. Virchows Arch 427: 295-301, 1995
13. Nemoto R, Hattori K, Uchida K, Shimazui T, Koiso K, Harada M: Estimation of growth fraction in situ in human bladder cancer with bromodeoxyuridine labeling. Br J Urol 65: 27-31, 1990
14. Brown DC, Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathol 17: 489-503, 1990
15. Zolzer F, Speer A, Pelzer T, Streffer C: Evidence for quiescent S-and G2-phase cells in human colorectal carcinomas: a flow cytometric study with the Ki-67 antibody. Cell Proliferation 28: 313-327, 1995
16. Cheng CL, Van Ness JW: On estimating linear relationships when both variables are subject to errors. JR Statist Soc B 56: 167-183, 1994
17. Efron B, Tibshirano RJ: An Introduction to the Bootstrap. Chapman & Hall, New York, 1993
18. McCullagh P, Neider JA: Generalized Linear Models. Chapman & Hall, New York, 1989 (2nd ed)
19. Going JJ, Stanton PD, Cooke TG: Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labeled in vivo with bromodeoxyuridine. J Clin Path 100: 218-222, 1993
20. Onda K, Davis R, Shibuya M, Wilson C, Hoshino T: Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74: 1921-1926, 1994
21. Verhoeven D, Bourgeois N, Derde MP, Kaufman L, Buyssens N: Comparison of cell growth in different parts of breast cancers. Histopathol 17: 505-509, 1990
22. Kamel OW, Franklin WA, Ringus JC, Meyer JS: Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134: 107-113, 1989
23. Rudas M, Gnant MFX, Mittlböck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A: Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res Treat 32: 165-175, 1994